Quantification and targeting of elusive neurotoxic amyloid oligomers

Kass, 2022, Aβ oligomer concentration in mouse and human brain and its drug induced reduction ex vivo, Cell Rep. Med, 3, 100630-1 2022, 2022 Alzheimer’s disease facts and figures, Alzheimer’s Dement., 18, 700, 10.1002/alz.12638 Sengupta, 2016, The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy, EBioMedicine, 6, 42, 10.1016/j.ebiom.2016.03.035 Brundin, 2010, Prion-like transmission of protein aggregates in neurodegenerative diseases, Nat. Rev. Mol. Cell Biol., 11, 301, 10.1038/nrm2873 Jaunmuktane, 2020, Invited Review: The role of prion-like mechanisms in neurodegenerative diseases, Neuropathol. Appl. Neurobiol., 46, 522, 10.1111/nan.12592 Kayed, 2004, Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases, J. Biol. Chem., 279, 46363, 10.1074/jbc.C400260200 Ono, 2018, Alzheimer’s disease as oligomeropathy, Neurochem. Int., 119, 57, 10.1016/j.neuint.2017.08.010 Lo Cascio, 2019, Toxic tau oligomers modulated by novel curcumin derivatives, Sci. Rep., 9, 19011 Plotkin, 2020, Passive immunotherapies targeting Aβ and tau in Alzheimer’s disease, Neurobiol. Dis., 144, 105010, 10.1016/j.nbd.2020.105010